Intercept trial of Obeticholic Acid posted on ClinicalTrials.gov A trial of Intercept's Obeticholic Acid was posted on ClinicalTrials.gov, with a stated main purpose to test the drug' effectiveness when used in patients with moderately severe alcoholic hepatitis. The researchers suspect that individuals with alcoholic hepatitis have certain abnormalities in how their body handles bile acids produced by the liver, the guidance said. Obeticholic acid has "been shown to affect bile acid abnormalities and thus it is possible that obeticholic acid may improve liver condition in individuals with alcoholic hepatitis," the website notes. Shares of Intercept are up 10%, or $27.38, to $305.00 in late morning trading. Reference Link
Deutsche Bank biotech analyst holds an analyst/industry conference call Biotech Analyst Young provides a review of the ICPT/GNFT thesis on an Analyst/Industry conference call to be held on October 22 at 11 am.